Overview

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-31

Target enrollment:

Participant gender:

Summary

This study is a Prospective, Single-arm, Phase II clinical trial. The purpose of this study is to find out if taking Etoposide Capsules combined With Bevacizumab and Iparomlimab and Tuvonralimab is safe and works well for people with platinum-resistant or platinum refractory ovarian cancer . Researchers will look at the Progression-Free Survival, Objective Response Rate, Overall Survival, safety, and any side effects.

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Treatments:

Bevacizumab
Etoposide